Summary
Zoetis Inc. reported strong performance in its 2021 10-K filing, showcasing robust revenue growth driven by both its U.S. and International segments. The company's diversified portfolio, with a significant contribution from companion animal products (60% of revenue), highlights its resilience and market leadership in the animal health sector. Key growth drivers include increasing pet ownership, rising demand for quality animal protein, and the company's continuous innovation in medicines and vaccines. Zoetis's financial health appears solid, with significant cash reserves and manageable debt, supporting its ongoing investments in research and development and strategic acquisitions to further expand its offerings in diagnostics, precision animal health, and digital solutions. Despite the positive financial outlook, investors should be aware of the competitive landscape and potential risks, including patent expirations for certain key products and the ongoing impact of global economic conditions and regulatory changes. The company's strategic focus on innovation, customer experience, digital leadership, and sustainability positions it well for future growth, making it an attractive prospect for long-term investors in the animal health industry.
Financial Highlights
53 data points| Revenue | $7.78B |
| Cost of Revenue | $2.30B |
| Gross Profit | $5.47B |
| SG&A Expenses | $2.00B |
| Interest Expense | $224.00M |
| Net Income | $2.03B |
| EPS (Basic) | $4.29 |
| EPS (Diluted) | $4.27 |
| Shares Outstanding (Basic) | 474.35M |
| Shares Outstanding (Diluted) | 476.72M |
Key Highlights
- 1Zoetis reported a 16% increase in total revenue to $7.78 billion in 2021, driven by strong performance in both the U.S. and International segments.
- 2Companion animal products represented 60% of total revenue, emphasizing the growing demand for pet healthcare, while livestock products accounted for 39%.
- 3The company's top two products, Apoquel and Simparica/Simparica Trio, each contributed approximately 10% of revenue, with the top five products contributing 33%.
- 4Research and Development (R&D) expenses increased by 10% to $508 million, reflecting continued investment in innovation and new product development.
- 5Zoetis maintained a strong liquidity position with $3.49 billion in cash and cash equivalents and robust operating cash flow.
- 6The company announced significant share repurchase programs, demonstrating a commitment to returning value to shareholders.
- 7Key product launches and expansions in diagnostics and precision animal health are strategically positioning Zoetis for continued growth in evolving market segments.